You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201901 - 201910 of 207699 results
  1. A pocket-sized device for personal exposure level assessment

    SBC: TF SENSORS, LLC            Topic: NIEHS

    DESCRIPTION (provided by applicant): A pocket-sized device for personal exposure level assessment Abstract Detecting environmental toxicants is critical for better understanding of the relationship between chemical exposures and many diseases, and for more effective prevention of the related diseases. Due to large variations in the individuals' genetic susceptibility and environmental exposu ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Tools to Study Mammalian Mutagenesis

    SBC: Litron Laboratories Ltd            Topic: NIEHS

    DESCRIPTION (provided by applicant): Despite the extensive work being performed to understand cancer and carcinogenic properties of chemicals and other agents, there are still gaps in our ability to efficiently identify carcinogens, and elucidate their mode(s) of action. The current state of assays designed to examine mutation and carcinogenic mechanisms are especially limited by their high costs ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Non-Invasive Treatment for Uveitis

    SBC: ACIONT, INC.            Topic: NEI

    DESCRIPTION (provided by applicant): The aim of this innovative proposal is to commercialize a non-invasive topical product that treats uveitis which is safe and easy to administer. Uveitis is the third leading cause of blindness in the United States. Heretofore, the primary treatment of intermediate and posterior uveitis has been either oral medications (with significant systemic side effects) or ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. System for Increasing Patient Access to Eye Exams for Diabetic Retinopathy

    SBC: AEON IMAGING LLC            Topic: NEI

    Project Summary / Abstract - EY020017 Phase IIB Competitive Renewal The overall goal of the proposed SBIR program is to implement and evaluate a low cost, portable retinal camera, the DLP-Cam, in a primary care system for diabetic retinopathy (DR) screening. Untreated DR has reached epidemic levels in underserved populations worldwide. To fully address this issue, DR screening must lead seamlessl ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Development and Commercialization of Ocular Diagnostic Test Based on Vitreous Pro

    SBC: OCULAR PROTEOMICS, LLC            Topic: NEI

    DESCRIPTION (provided by applicant): Age-related macular degeneration (AMD) is the leading cause of vision loss and blindness in people over age 60 in the developed world. Progression of this disease results in the loss of the ability to perform activitieshighly correlaed with quality of life. This disease progression is not well understood and treatments address only portions of the underlying me ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Small Incision Artificial Cornea

    SBC: KERAMED            Topic: NEI

    DESCRIPTION (provided by applicant): The objective of this grant proposal is to perform a clinical study which will allow the first foldable and injectable artificial cornea, the KeraKlear, to be used in the United States market for treatment of corneal blindness. This device may be implanted through an incision size that is approximately 1/10th the size of the incision that is required for the mo ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Surgical Adhesive for Seroma Prevention

    SBC: COHERA MEDICAL, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Seroma formation (fluid accumulation in the wound) is among the most common post-surgical complications, occurring in up to 50% of certain surgical procedures. TissuGlu(R) Surgical Adhesive is designed to adhere flaps of tissue and prevent the accumulation of fluid in surgical wounds, thereby reducing the need for drains and improving the time to recovery. Trad ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  8. New Reagents for RNA-based Therapeutic Technologies

    SBC: AM BIOTECHNOLOGIES, LLC            Topic: NIGMS

    DESCRIPTION: New Reagents for RNA-based Therapeutic Technologies Abstract Functional RNA molecules such as aptamers, siRNAs, miRNAs, and related compounds have enormous potential as human therapeutics and as tools for elucidating gene regulation in vivo.To reach this potential, such molecules must be highly potent and highly stable. Unmodified RNAs typically do not come close to meeting these req ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  9. A platform to predict side-effect targets for drugs

    SBC: Seachange Pharmaceuticals, Inc.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Bioactive small molecules can act on multiple targets, and these off-target activities underlie many of the adverse reactions from which drugs suffer. The motivating idea of this proposal is that these Adverse Drug Reaction (ADR) targets may be predicted comprehensively and systematically using chemoinformatic inference. The Similarity Ensemble Approach (SEA) ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Using Aldehyde Tags to Generate Site-Specifically Modified Antibody Drug Conjugat

    SBC: REDWOOD BIOSCIENCE, INC.            Topic: NIGMS

    DESCRIPTION: Monoclonal antibodies (mAbs) have demonstrated considerable utility in cancer treatment. There are a number of unmodified mAbs currently available for patient treatment. However, in order to improve the therapeutic value of mAbs considerableeffort is being focused on enhancing their activity by attaching cytotoxic drugs to the biomolecules. This combination of small molecule drugs an ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government